Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
2024 · New England Journal of Medicine · 810 citations
https://doi.org/10.1056/nejmoa2312117
S
Shilpa Gupta
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
551
Papers
15.2K
Citations
49
h-index
151
i10-index
Shilpa Gupta is an academic researcher from Dr. A.P.J. Abdul Kalam Technical University. The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Cancer Immunotherapy and Biomarkers & Urinary and Genital Oncology Studies. The author has an h-index of 49, co-authored 469 publications.
ORCID: 0000-0002-8775-503XPapers by this author
worksProstate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
2023 · Journal of the National Comprehensive Cancer Network · 509 citations
https://doi.org/10.6004/jnccn.2023.0050
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
2018 · British Journal of Cancer · 443 citations
https://doi.org/10.1038/s41416-018-0131-9
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial
2023 · European Urology · 55 citations
https://doi.org/10.1016/j.eururo.2023.03.030
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
2025 · Journal for ImmunoTherapy of Cancer · 29 citations
https://doi.org/10.1136/jitc-2024-010311
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201
2023 · Annals of Oncology · 27 citations
https://doi.org/10.1016/j.annonc.2023.10.794
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat